According to the American Diabetes Association’s Standards of Care 2024, if glycemic targets are no longer met with metformin (with or without long-acting insulin), GLP-1 receptor agonist (GLP-1 RA) therapy should be considered [9]. Here, GCG is linked to diabetes mellitus.